AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) is among those stocks that we come back to offer updates on as often as we can. We’ve tracked this story over quite a long time period now, and the company rarely goes more than a few days between updates. Its transparency is one of the things we like best about Aurora.


One of the aspects of the Aurora narrative that we’ve been paying careful attention to is the company’s takeover of CanniMed, which is set to conclude presently, and is an integral oiece in the formation of the company’s proposed science division.


AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) announced the appointments of Dr. Shane Morris as Vice President Product Development and Regulatory Affairs, and that of Dr. Kelly Narine as Vice President of Research. The appointments are part of Aurora`s continued initiative to create a dedicated scientific division, tasked with the development and launch of new technologies and products, as well as to conduct advanced scientific research.


In his newly created role of VP of Product Development and Regulatory Affairs, Dr. Morris will be responsible for the development and market introduction of new cannabis products, as well as provide strategic, regulatory leadership on all new cannabis products. The appointment of Dr. Morris reflects Aurora`s commitment to rigorous science-based innovation, driving the launch of higher-margin cannabis-based products for both the medical market and the adult consumer use market, once legalized.


Dr. Morris, an experienced executive in the cannabis industry since 2015, was previously part of the senior leadership team at Hydropothecary, a Quebec based licensed producer. His proven expertise in quality assurance, cannabis operations, regulatory affairs and science will prove essential in bringing new cannabis products to market efficiently and effectively. Dr. Morris holds a doctorate from the National University of Ireland in biotechnology and publishes/lectures widely on regulation, risk and policy.


Dr. Kelly Narine will be leading the Company’s research innovation and research partnerships portfolios. Her work will be focused on human health outcomes, product safety, plant biotechnology, and early product development & testing. Dr. Narine has deep expertise in successfully translating promising research into positive human health outcomes. Her appointment and the initiatives that the Company intends on undertaking will drive the development of a significant pipeline of science-based and -backed offerings, which management believes will resonate strongly with the large and rapidly growing domestic and international cannabis markets.


“These key appointments reflect our commitment to a science-based approach to innovation, product and technology development,” said Terry Booth, CEO. “Our intention is to develop a strong pipeline of new, higher-margin revenue streams to capitalize on the tremendous opportunity in the medical cannabis and adult consumer use markets. Science and innovation are cornerstones of our global growth strategy, and with Shane and Kelly we now have highly experienced leadership for the science division. Furthermore, once completed, the CanniMed acquisition will provide a strong foundation to build our medical science division on, and help further differentiate and diversify our product offering.” (Source: Canada Newswire)


We’re proud to say we’ve been tracking Aurora (and calling it one of our favorite Canadian Cannabis plays) for such a long time. The progress the company has made, even in just the last year, has been nothing short of astounding. We are especially eager to track its activities regarding this new science division, but aslo in the upcoming recreational legalization in Canada, which is now less than four months away. Stay locked on and be sure you’re signed up for our 100% free smallcap newsletter. It’s as easy as that! Simply submit your primary active email address in the box below. Subscribe now!



Disclosure: No one at Street Register has been compensated in any way for the publishing of this article, nor do we hold any position in ACBFF stock, short or long.